Target Name: WDR47
NCBI ID: G22911
Review Report on WDR47 Target / Biomarker Content of Review Report on WDR47 Target / Biomarker
WDR47
Other Name(s): WDR47_HUMAN | Neuronal enriched MAP-interacting protein | neuronal enriched MAP-interacting protein | WD repeat-containing protein 47 | WDR47 variant 1 | KIAA0893 | WD repeat domain 47, transcript variant 1 | Neuronal enriched MAP interacting protein | nemitin | WD repeat domain 47 | Nemitin | WD repeat-containing protein 47 (isoform 2) | WDR47 variant 2 | WD repeat-containing protein 47 (isoform 1) | WD repeat domain 47, transcript variant 2

Understanding The Potential of WDR47 as A Drug Target Or Biomarker

WDR47 (WDR47_HUMAN) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug or biomarker has led to a great deal of interest and discussion in the scientific community.

WDR47 is a RNA molecule that is located in the nucleus of the human cell. It is characterized by its unique structure, which consists of a single RNA molecule that is composed of 251 amino acids. The molecule has a circular shape and is composed of a stem-loop and a 3' end. The stem-loop is the central region of the molecule and is composed of a series of alternating double-stranded regions.

WDR47 has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis (programmed cell death). It has also been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of WDR47 are associated with poor prognosis in cancer patients.

One of the reasons for the interest in WDR47 is its potential as a drug target. The unique structure of the molecule makes it difficult to predict the interactions between the molecule and potential drugs. However, studies have shown that WDR47 can interact with a variety of drugs, including inhibitors of the PI3K/Akt signaling pathway, which is a pathway that is involved in cell growth and survival.

In addition to its potential as a drug target, WDR47 has also been shown to be a potential biomarker for various diseases. Its unique structure and function make it difficult to predict the interactions between the molecule and potential biomarkers. However, studies have shown that WDR47 can interact with a variety of proteins, including those that are involved in cell adhesion, migration, and apoptosis. This suggests that WDR47 may be a useful biomarker for certain diseases.

Another potential use of WDR47 is its potential as a therapeutic agent. The unique structure and function of the molecule make it difficult to predict the interactions between the molecule and the cell. However, studies have shown that WDR47 can interact with a variety of proteins, including those that are involved in cell adhesion, migration, and apoptosis. This suggests that WDR47 may be a useful therapeutic agent for certain diseases.

In conclusion, WDR47 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases. Its unique structure and function make it difficult to predict the interactions between the molecule and potential drugs, but studies have shown that it can interact with a variety of proteins involved in cell growth, differentiation, and apoptosis. Further research is needed to fully understand the potential of WDR47 as a drug target or biomarker.

Protein Name: WD Repeat Domain 47

The "WDR47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR